Treatment
Fludarabine clinical trials
We’re tracking 300 recruiting studies that include Fludarabine, each written for real people, not researchers, below.
Recruiting studies
- NCT06809699RecruitingPhase 1
Stem cell transplant using a partially matched family donor
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hangzhou, ChinaAges 18–60 - NCT07428993RecruitingPhase 2
CAR T-Cell Therapy for High-Risk Osteosarcoma
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07416682RecruitingEarly Phase 1
CAR-T cell therapy for high-risk plasma cell cancers
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07411599RecruitingPhase 1/Phase 2
CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
Houston, TexasAges 18 years+ - NCT06829472RecruitingPhase 3
Comparing melphalan doses before stem cell transplant for AML/MDS
This trial compares two different doses of a chemotherapy drug (melphalan) as part of the conditioning treatment before a stem cell transplant. The goal is to find which dose is safer and more effective for people with AML or MDS.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT07390539RecruitingPhase 1
CAR T cells targeting B7-H3 for brain tumors
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
Boston, MassachusettsAges 2–21 - NCT07358260RecruitingPhase 1
B7-H3 CAR T cells for solid tumors in children and young adults
This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.
Boston, MassachusettsAges 9 months–30 years - NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT07288073RecruitingPhase 2
TIL Therapy for Advanced Skin Cancer Patients
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
Boston, MassachusettsAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75 - NCT07227571RecruitingPhase 1
CAR T cells for advanced osteosarcoma
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
Seattle, WashingtonAges 1–75 - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT03643276RecruitingPhase 3
Study of treatment plans for children with leukemia
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
SydneyAges Up to 17 years - NCT07174427RecruitingPhase 3
Study of a new cell therapy for synovial sarcoma
This trial tests a new cell therapy called TBI-1301 (Mip-cel) for people with synovial sarcoma that has spread or come back after chemotherapy. It is designed to help your immune system attack the cancer cells that have a specific marker (NY-ESO-1).
Osaka, OsakaAges 18 years+ - NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT07162038RecruitingPhase 1
CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Bethesda, MarylandAges 18–75 - NCT07149857RecruitingPhase 2
A study of CAR-T therapy for newly diagnosed multiple myeloma
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
San Francisco, CaliforniaAges 18–80 - NCT07144462RecruitingEarly Phase 1
Testing a new drug for people with certain autoimmune diseases that have come back or not responded to treatment
This trial is testing a new injection, NEUK203-215, in adults aged 18-65 with certain autoimmune diseases (like lupus, scleroderma, inflammatory myopathy, or a skin blistering condition) that have relapsed or not responded to standard therapy. The goal is to see if it is safe, tolerable, and may help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07115745RecruitingPhase 1
Donor CAR T cells for severe autoimmune diseases
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07101432RecruitingPhase 1
Radiation plus engineered NK cells for advanced head and neck cancer
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
Houston, TexasAges 18 years+ - NCT07105176RecruitingPhase 1
TIL therapy for advanced lung cancer after first-line treatment
This trial tests a new treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer. The cells are taken from a tumor, multiplied in a lab, and given back to you to help your body attack the cancer.
Guangzhou, GuangdongAges 18–75
Common questions
- Are there clinical trials studying Fludarabine?
- Yes. Clin2 currently lists 300 recruiting studies that include Fludarabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Fludarabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Fludarabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Fludarabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.